- Home
- BLNK vs ZURA Comparison
BLNK vs ZURA Comparison
Compare BLNK & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- ZURA
- Stock Information
- Founded
- BLNK 2009
- ZURA 2022
- Country
- BLNK United States
- ZURA United States
- Employees
- BLNK N/A
- ZURA N/A
- Industry
- BLNK Industrial Specialties
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLNK Consumer Discretionary
- ZURA Health Care
- Exchange
- BLNK Nasdaq
- ZURA Nasdaq
- Market Cap
- BLNK 73.4M
- ZURA 76.6M
- IPO Year
- BLNK N/A
- ZURA N/A
- Fundamental
- Price
- BLNK $0.70
- ZURA $0.99
- Analyst Decision
- BLNK Buy
- ZURA Buy
- Analyst Count
- BLNK 8
- ZURA 7
- Target Price
- BLNK $2.61
- ZURA $14.33
- AVG Volume (30 Days)
- BLNK 2.4M
- ZURA 520.6K
- Earning Date
- BLNK 05-12-2025
- ZURA 05-08-2025
- Dividend Yield
- BLNK N/A
- ZURA N/A
- EPS Growth
- BLNK N/A
- ZURA N/A
- EPS
- BLNK N/A
- ZURA N/A
- Revenue
- BLNK $109,383,000.00
- ZURA N/A
- Revenue This Year
- BLNK N/A
- ZURA N/A
- Revenue Next Year
- BLNK $28.49
- ZURA N/A
- P/E Ratio
- BLNK N/A
- ZURA N/A
- Revenue Growth
- BLNK N/A
- ZURA N/A
- 52 Week Low
- BLNK $0.63
- ZURA $0.97
- 52 Week High
- BLNK $3.75
- ZURA $5.56
- Technical
- Relative Strength Index (RSI)
- BLNK 41.86
- ZURA 34.02
- Support Level
- BLNK $0.67
- ZURA $0.99
- Resistance Level
- BLNK $0.78
- ZURA $1.06
- Average True Range (ATR)
- BLNK 0.04
- ZURA 0.08
- MACD
- BLNK -0.00
- ZURA -0.01
- Stochastic Oscillator
- BLNK 24.56
- ZURA 0.00
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.